Market Access Impact: Rheumatoid Arthritis (US) 2016

NEW YORK, Nov. 17, 2017 /PRNewswire/ -- Description

Compare 9 major RA therapies. Find out if prescription barriers cost your brand market share

Read the full report: https://www.reportlinker.com/p04833583

In the US, market barriers affect nearly a quarter of all rheumatoid arthritis (RA) prescriptions, but they don't affect all brands equally. Our survey of 100 rheumatologists shows that one brand is poised to move out of seventh place, and all the way into fourth, if it can find a way to overcome key barriers.

Find out which one, and learn how barriers affect market share for 8 other brands, in Market Access Impact: Rheumatoid Arthritis (US).
The report covers major therapies from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Janssen Biotech, Pfizer, Roche, and UCB. Handy graphs and charts show you at a glance which of 7 different barriers cost your brand the most market share, and which ones help you take the most share from competitors.

Top Takeaways
- All brands are widely prescribed: More than 60% of surveyed doctors prescribe all of the surveyed brands, and 90% of them or more prescribe the top three brands.
- Barriers affect almost a quarter of all prescriptions: But cost and market access barriers have a greater impact than all other barriers combined.
- Not all brands are affected equally: More than half of the barriers covered in the report affect one or two brands more than the rest.
- Three brands see modest share gains: Barriers helped the three most prescribed brands gain market share. The other 6 brands either lose share or break even.
- Barriers are holding one brand back: The top three barriers affect this brand more than any other, so it's not surprising that it loses the most share overall. If barriers didn't exist this brand would vault from 7th place to 4th.
- Doctors are almost always willing to consider brands they don't currently prescribe: Brand perception and awareness are excellent overall.

Insight into 9 Major Rheumatoid Arthritis Drugs
- Actemra (tocilizumab; Roche)
- Cimzia (certolizumab pegol; UCB)
- Enbrel (etanercept; Amgen)
- Humira (adalimumab; AbbVie)
- Orencia (abatacept; Bristol-Myers Squibb)
- Remicade (infliximab; Janssen Biotech)
- Rituxan (rituximab; Roche/Biogen)
- Simponi (golimumab; Janssen Biotech)
- Xeljanz (tofacitinib; Pfizer)

Exploring Market Access Barriers

Market Access Impact: Rheumatoid Arthritis (US) explores key issues affecting RA drug manufacturers.

You'll learn:
- How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 100 US-based rheumatologists, chosen from the largest community of validated physicians in the world.

- All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with rheumatoid arthritis in total in the last month
- We conducted the survey between November 1st and 4th, 2016.


Read the full report: https://www.reportlinker.com/p04833583

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker